A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson, Manali Kamdar, Brian JP Huntly, Carlos Fernandez De larrea, Raul Cordoba, Maria-Victoria Mateos, Adrian Alegre, Won-Seog Kim, Jin Seok Kim, Mark Dawson, Paul Sung-Hao Yeh, Faisal Basheer, Paolo Gallipoli, Aristeidis Chaidos, Alejandro Martin, Thierry Horner, James Winnberg, Lijoy K Mathew, Jeffrey Botbyl, Natalie Karpinich Show all